Bayer Products Give Schering Cross-Promotion Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
The acquisition of Bayer's primary care products will allow Schering-Plough to cross-market its own drugs to former Bayer customers
You may also be interested in...
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.
Schering-Plough Posaconazole NDA User Fee Date Is March 2005
Potential spring launch of invasive fungal infection agent Noxafil could be Schering’s next new product after Vytorin; the Zetia/Zocor combination’s user fee date is July 24. Schering’s remaining NME in Phase III is another anti-infective.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability